Signature program: a platform of basket trials

Oncotarget
Eric D SlosbergAugust Salvado

Abstract

Investigating targeted therapies can be challenging due to diverse tumor mutations and slow patient accrual for clinical studies. The Signature Program is a series of 8 phase 2, agent-specific basket protocols using a rapid study start-up approach involving no predetermined study sites. Each protocol evaluated 1 agent (buparlisib, dovitinib, binimetinib, encorafenib, sonidegib, BGJ398, ceritinib, or ribociclib) in patients with solid or hematologic malignancies and an actionable mutation. The primary endpoint of each study was the clinical benefit rate (ie, complete or partial response, or stable disease) at 16 weeks. A total of 192 individual sites were opened in the United States, with a median start-up time of 3.6 weeks. The most common tumor types among the 595 treated patients were colorectal (9.2%), non-small cell lung adenocarcinoma (9.1%), and ovarian (8.4%). Frequent genetic alterations were in PIK3CA, RAS, p16, and PTEN. Overall, 30 partial or complete responses were observed with 6 compounds in 16 tumor types. The Signature Program presents a unique and successful approach for rapid signal finding across multiple tumors and allowed various agents to be evaluated in patients with rare alterations. Incorporating these ...Continue Reading

References

May 18, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sang Hoon LeeCarla Heise
Feb 18, 2006·Nature Reviews. Drug Discovery·Donald A Berry
Jan 16, 2013·Cancer Discovery·Matthew J Ellis, Charles M Perou
Aug 29, 2013·Clinical Trials : Journal of the Society for Clinical Trials·Scott M BerryDonald A Berry
Sep 21, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Julieann RaderJohn M Maris
Jun 10, 2010·ACS Medicinal Chemistry Letters·Shifeng PanMarion Dorsch
Feb 11, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ariel Lopez-ChavezGiuseppe Giaccone
Feb 11, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Amanda J Redig, Pasi A Jänne
Mar 27, 2015·Clinical Pharmacology and Therapeutics·B P KangA Salvado
May 21, 2015·American Society of Clinical Oncology Educational Book·Sumithra J MandrekarRichard Simon
Aug 20, 2015·The New England Journal of Medicine·David M HymanJosé Baselga
Nov 13, 2015·Clinical Pharmacology and Therapeutics·D A Berry
Mar 2, 2016·Journal of Health Economics·Joseph A DiMasiRonald W Hansen
Mar 5, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Evgeny YakirevichHoward Safran
Jul 15, 2016·The New England Journal of Medicine·John W ParkUNKNOWN I-SPY 2 Investigators
Jul 15, 2016·The New England Journal of Medicine·Hope S RugoUNKNOWN I-SPY 2 Investigators
Dec 14, 2016·The New England Journal of Medicine·Rachel E ShermanRobert M Califf
Jul 6, 2017·The New England Journal of Medicine·Janet Woodcock, Lisa M LaVange
Sep 14, 2017·Contemporary Clinical Trials·Sonya Das, Andrew W Lo
Jan 11, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John D HainsworthRazelle Kurzrock
Jan 1, 2013·Therapeutic Innovation & Regulatory Science·Mary Jo LambertiKen Getz

❮ Previous
Next ❯

Citations

Oct 28, 2018·Nature Reviews. Clinical Oncology·Masaru Katoh
Jan 14, 2019·Clinical Pharmacology and Therapeutics·Myrto LeeMichael S Ringel
Dec 14, 2018·The Annals of Pharmacotherapy·Kaitlin RasconEkim Ekinci
Jul 25, 2019·Blood Advances·Amy BurdDavid R Gandara
Oct 14, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Keith T FlahertyUNKNOWN NCI-MATCH team
Jul 25, 2019·Contemporary Clinical Trials Communications·Ellie G SidenEdward J Mills
Aug 11, 2020·EClinicalMedicine·Ramon ColomerMiguel Quintela-Fandino
Oct 24, 2020·Cancer Treatment Reviews·Christian Dittrich
Jul 6, 2020·Clinical Therapeutics·Elias Laurin MeyerFranz König
Jan 19, 2019·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Julien PéronPatrick Schöffski
Jun 28, 2021·Seminars in Cancer Biology·Richard RosenquistAnna Schuh
Sep 21, 2020·Seminars in Cancer Biology·Apostolia M TsimberidouRazelle Kurzrock

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy

Clinical Trials Mentioned

NCT01833169
NCT01831726
NCT01885195
NCT01981187
NCT02002689
NCT02160041
NCT02186821
NCT02187783

Software Mentioned

Signature Program
MyPathway
ProfilER
Signature

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.